Levosimendan and Global Longitudinal Strain Assessment in Sepsis (GLASSES 1): a study protocol for an observational study
Introduction Cardiogenic shock is a condition of low cardiac output that represents the end stage of a progressive deterioration of cardiac function. The main cause is ischaemic heart disease, but there are several non-ischaemic causes, including sepsis. The use of levosimendan in cardiogenic shock...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2020-09-01
|
| Series: | BMJ Open |
| Online Access: | https://bmjopen.bmj.com/content/10/9/e037188.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841554759049281536 |
|---|---|
| author | Iacopo Cappellini Alessandra Melai Lucia Zamidei Maddalena Parise Simone Cipani Guglielmo Consales |
| author_facet | Iacopo Cappellini Alessandra Melai Lucia Zamidei Maddalena Parise Simone Cipani Guglielmo Consales |
| author_sort | Iacopo Cappellini |
| collection | DOAJ |
| description | Introduction Cardiogenic shock is a condition of low cardiac output that represents the end stage of a progressive deterioration of cardiac function. The main cause is ischaemic heart disease, but there are several non-ischaemic causes, including sepsis. The use of levosimendan in cardiogenic shock during sepsis is still under debate.Methods We are conducting an observational, single-centre, not-for-profit study enrolling patients aged 18–80 years old admitted to the intensive care unit with a diagnosis of septic shock. Patients will be monitored with the EV1000/VolumeView device (Edwards Lifesciences, Irvine, USA). Patients with cardiac index (CI) values <2.5 L/min/m2 and/or stroke volume index (SVI) <30 mL/beat/m2 are considered eligible for the study. Enrolled participants will undergo an echocardiographic examination using the Vivid S6 ultrasound machine (General Electric, Northville, Michigan) and a 3.6 MHz cardiology probe through which the apical projections of chambers 2, 3 and 4 will be acquired; this is necessary to calculate the global longitudinal strain (GLS) using EchoPAC* Clinical Workstation Software (General Electric). A dobutamine infusion will be started in these patients; 24 hours later CI and SVI will be recalculated using EV1000/VolumeView and then a levosimendan infusion will begin for 24 hours. Once the infusion cycle of the calcium-sensitising drug has been carried out, the infusion of dobutamine will be reduced until it stops, and the CI, SVI, GLS and arterial elastance (Ea):Ventricular Elastance (Ees) will be re-evaluated. The primary endpoint is recovery of GLS ≥15% and the secondary endpoint is a relative reduction in mortality of 15%.Ethics and dissemination The investigators declare that the study will be conducted in full compliance with international regulations (EU Directive 2016/679/EC) and national implementation (DM 15 July 1997; 211/2003; 200/2007) regarding the clinical trial and the principles of the Declaration of Helsinki. Study results will be disseminated through peer-reviewed journals and conferences. Ethical approval for this study has been given by Comitato Etico Regione Toscana - Area Vasta Centro, Florence, Italy (ethical committee number: 13875_oss) on 25 May 2019 (Chairperson Professor Marco Marchi).Trial registration number NCT04141410. |
| format | Article |
| id | doaj-art-1ab6aa0b6a4743e8b3897d61e0b06751 |
| institution | Kabale University |
| issn | 2044-6055 |
| language | English |
| publishDate | 2020-09-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | BMJ Open |
| spelling | doaj-art-1ab6aa0b6a4743e8b3897d61e0b067512025-01-08T09:30:09ZengBMJ Publishing GroupBMJ Open2044-60552020-09-0110910.1136/bmjopen-2020-037188Levosimendan and Global Longitudinal Strain Assessment in Sepsis (GLASSES 1): a study protocol for an observational studyIacopo Cappellini0Alessandra Melai1Lucia Zamidei2Maddalena Parise3Simone Cipani4Guglielmo Consales5Department of Critical Care Section of Anesthesiology and Intensive Care, Azienda USL Toscana Centro, Prato, ItalyDepartment of Critical Care Section of Anesthesiology and Intensive Care, Azienda USL Toscana Centro, Prato, ItalyDepartment of Critical Care Section of Anesthesiology and Intensive Care, Azienda USL Toscana Centro, Prato, ItalyDepartment of Critical Care Section of Anesthesiology and Intensive Care, Azienda USL Toscana Centro, Prato, ItalyDepartment of Critical Care Section of Anesthesiology and Intensive Care, Azienda USL Toscana Centro, Figline Valdarno, ItalyDepartment of Critical Care Section of Anesthesiology and Intensive Care, Azienda USL Toscana Centro, Prato, ItalyIntroduction Cardiogenic shock is a condition of low cardiac output that represents the end stage of a progressive deterioration of cardiac function. The main cause is ischaemic heart disease, but there are several non-ischaemic causes, including sepsis. The use of levosimendan in cardiogenic shock during sepsis is still under debate.Methods We are conducting an observational, single-centre, not-for-profit study enrolling patients aged 18–80 years old admitted to the intensive care unit with a diagnosis of septic shock. Patients will be monitored with the EV1000/VolumeView device (Edwards Lifesciences, Irvine, USA). Patients with cardiac index (CI) values <2.5 L/min/m2 and/or stroke volume index (SVI) <30 mL/beat/m2 are considered eligible for the study. Enrolled participants will undergo an echocardiographic examination using the Vivid S6 ultrasound machine (General Electric, Northville, Michigan) and a 3.6 MHz cardiology probe through which the apical projections of chambers 2, 3 and 4 will be acquired; this is necessary to calculate the global longitudinal strain (GLS) using EchoPAC* Clinical Workstation Software (General Electric). A dobutamine infusion will be started in these patients; 24 hours later CI and SVI will be recalculated using EV1000/VolumeView and then a levosimendan infusion will begin for 24 hours. Once the infusion cycle of the calcium-sensitising drug has been carried out, the infusion of dobutamine will be reduced until it stops, and the CI, SVI, GLS and arterial elastance (Ea):Ventricular Elastance (Ees) will be re-evaluated. The primary endpoint is recovery of GLS ≥15% and the secondary endpoint is a relative reduction in mortality of 15%.Ethics and dissemination The investigators declare that the study will be conducted in full compliance with international regulations (EU Directive 2016/679/EC) and national implementation (DM 15 July 1997; 211/2003; 200/2007) regarding the clinical trial and the principles of the Declaration of Helsinki. Study results will be disseminated through peer-reviewed journals and conferences. Ethical approval for this study has been given by Comitato Etico Regione Toscana - Area Vasta Centro, Florence, Italy (ethical committee number: 13875_oss) on 25 May 2019 (Chairperson Professor Marco Marchi).Trial registration number NCT04141410.https://bmjopen.bmj.com/content/10/9/e037188.full |
| spellingShingle | Iacopo Cappellini Alessandra Melai Lucia Zamidei Maddalena Parise Simone Cipani Guglielmo Consales Levosimendan and Global Longitudinal Strain Assessment in Sepsis (GLASSES 1): a study protocol for an observational study BMJ Open |
| title | Levosimendan and Global Longitudinal Strain Assessment in Sepsis (GLASSES 1): a study protocol for an observational study |
| title_full | Levosimendan and Global Longitudinal Strain Assessment in Sepsis (GLASSES 1): a study protocol for an observational study |
| title_fullStr | Levosimendan and Global Longitudinal Strain Assessment in Sepsis (GLASSES 1): a study protocol for an observational study |
| title_full_unstemmed | Levosimendan and Global Longitudinal Strain Assessment in Sepsis (GLASSES 1): a study protocol for an observational study |
| title_short | Levosimendan and Global Longitudinal Strain Assessment in Sepsis (GLASSES 1): a study protocol for an observational study |
| title_sort | levosimendan and global longitudinal strain assessment in sepsis glasses 1 a study protocol for an observational study |
| url | https://bmjopen.bmj.com/content/10/9/e037188.full |
| work_keys_str_mv | AT iacopocappellini levosimendanandgloballongitudinalstrainassessmentinsepsisglasses1astudyprotocolforanobservationalstudy AT alessandramelai levosimendanandgloballongitudinalstrainassessmentinsepsisglasses1astudyprotocolforanobservationalstudy AT luciazamidei levosimendanandgloballongitudinalstrainassessmentinsepsisglasses1astudyprotocolforanobservationalstudy AT maddalenaparise levosimendanandgloballongitudinalstrainassessmentinsepsisglasses1astudyprotocolforanobservationalstudy AT simonecipani levosimendanandgloballongitudinalstrainassessmentinsepsisglasses1astudyprotocolforanobservationalstudy AT guglielmoconsales levosimendanandgloballongitudinalstrainassessmentinsepsisglasses1astudyprotocolforanobservationalstudy |